TRINTELLIX® (vortioxetine) is indicated for the treatment of Major Depressive Disorder (MDD) in adults.

Patient portrayal. 
Individual results may vary.

Dosing &
Administration

How does dosing fit into the story?

TRINTELLIX has once-daily oral dosing with or without food1

TRINTELLIX is available in 3 strengths

TRINTELLIX recommended dose is 20 mg/day, as tolerated

Recommended starting dose: TRINTELLIX (vortioxetine) 10 mg once daily. Increase as tolerated to 20 mg once daily, or continue on 10 mg once daily. 5 mg tablets may be used for titration in patients who do not tolerate higher doses.

Tablets shown not actual size.

  • The efficacy and safety of doses above 20 mg/day have not been evaluated1
  • Prior to initiating treatment with TRINTELLIX, screen patients for personal or family history of bipolar disorder, mania, or hypomania1
  • The maximum dose is 10 mg/day in patients who are known CYP2D6 poor metabolizers1
  • Although patients can abruptly discontinue therapy with TRINTELLIX, it is recommended that doses of 15 mg/day or 20 mg/day be reduced to 10 mg/day for 1 week prior to discontinuation1
    • In placebo-controlled trials, some patients experienced transient adverse reactions, such as headache and muscle tension, following abrupt discontinuation
  • Concomitant administration of TRINTELLIX and strong CYP2D6 inhibitors or strong CYP inducers may require a dose adjustment of TRINTELLIX1

For additional dosing information, please see the Full Prescribing Information.

Drug interactions

Clinically important drug interactions with TRINTELLIX1

Drug ClassClinical Impact & Recommendations

Monoamine Oxidase Inhibitors

selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue

CONCOMITANT USE WITH TRINTELLIX INCREASES THE RISK OF SEROTONIN SYNDROME

MAOIs for psychiatric disorders are contraindicated with TRINTELLIX or within 21 days of stopping TRINTELLIX.

TRINTELLIX is contraindicated within 14 days of stopping MAOIs for psychiatric disorders.

Starting TRINTELLIX in patients on linezolid or IV methylene blue is also contraindicated.

Other Serotonergic Drugs

Other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St. John's Wort

CONCOMITANT USE WITH TRINTELLIX INCREASES THE RISK OF SEROTONIN SYNDROME

Monitor for serotonin syndrome when TRINTELLIX is coadministered with other serotonergic drugs.

If serotonin syndrome occurs, discontinue TRINTELLIX and other serotonergic drugs, and initiate supportive treatment.

Strong CYP2D6 Inhibitors

bupropion, fluoxetine, paroxetine, quinidine

CONCOMITANT USE WITH TRINTELLIX INCREASES TRINTELLIX PLASMA LEVELS

Reduce the TRINTELLIX dose by half.

When discontinuing a strong CYP2D6 inhibitor, increase TRINTELLIX to its original dose.

Strong CYP Inducers

rifampin, carbamazepine, phenytoin

CONCOMITANT USE WITH TRINTELLIX DECREASES TRINTELLIX PLASMA LEVELS

Consider increasing the dose of TRINTELLIX when coadministered for more than 14 days.

The maximum TRINTELLIX dose should not be greater than three times the original TRINTELLIX dose.

When discontinuing a strong CYP inducer, reduce TRINTELLIX within 14 days to its original dose.

Antiplatelet Drugs and Anticoagulants

aspirin, clopidogrel, heparin, warfarin

CONCOMITANT USE WITH TRINTELLIX MAY POTENTIATE BLEEDING RISK

Inform patients of increased bleeding risk.

For patients on warfarin, monitor INR carefully when initiating, titrating or discontinuing TRINTELLIX.

Drugs Highly Bound to Plasma Protein

warfarin

CONCOMITANT USE WITH TRINTELLIX MAY INCREASE FREE TRINTELLIX PLASMA LEVELS OR OTHER HIGHLY PROTEIN-BOUND DRUG LEVELS

Monitor for adverse reactions.

Reduce dosage of TRINTELLIX or other highly protein-bound drugs as needed.

Note: Class examples do not include all possible class members.

Abbreviations: INR, International Normalized Ratio; IV, Intravenous; MAOIs, Monoamine oxidase inhibitors; NSAIDs, Nonsteroidal anti-inflammatory drugs; SNRIs, Serotonin-norepinephrine reuptake inhibitors; SSRIs, Selective serotonin reuptake inhibitors.

For additional Drug Interactions information, please see the ​​​Full Prescribing Information.

Tools for your patients and practice

Leaving TRINTELLIXHCP.COM

By clicking “Continue,” you will be leaving a Takeda controlled website for a third-party website.

Please note that Takeda is not responsible or liable for any third-party website, and the website may not be appropriate for all audiences.

CONTINUE
CANCEL

  1. Trintellix (vortioxetine) prescribing information. Takeda Pharmaceuticals.
  2. Alvarez E, Perez V, Dragheim M, Loft H, Artigas F. Int J Neuropsychopharmacol. 2012;15(5):589‑600.
  3. Henigsberg N, Mahableshwarkar AR, Jacobsen P, Chen Y, Thase ME. J Clin Psychiatry. 2012;73(7):953‑959.
  4. Boulenger J-P, Loft H, Olsen CK. Int Clin Psychopharmacol. 2014;29(3):138‑149.
  5. Mahableshwarkar AR, Jacobsen P, Chen Y, Serenko M, Trivedi MH. Psychopharmacology (Berl). 2015;232(12):2061‑2070.
  6. Jacobsen P, Mahableshwarkar AR, Serenko M, Chan S, Trivedi MH. J Clin Psychiatry. 2015;76(5):575‑582.
  7. Katona C, Hansen T, Olsen CK. Int Clin Psychopharmacol. 2012;27(4):215‑223.
  8. Costa SL, Genova HM, DeLuca J, Chiaravalloti ND. Mult Scler. 2017;23(6):772‑789.
  9. McIntyre RS, Lophaven S, Olsen CK. Int J Neuropsychopharmacol. 2014;17(10):1557‑1567.
  10. Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y, Keefe RSE. Neuropsychopharmacology. 2015;40(8):2025‑2037.
  11. Data on file. Takeda Pharmaceuticals.
  12. Data on file. Lundbeck.
  13. FDA updates Trintellix® (vortioxetine) label to include data showing improvement in processing speed, an important aspect of cognitive function in acute Major Depressive Disorder (MDD). News release. GlobeNewswire. May 2, 2018.
  14. Boulenger J-P, Loft H, Florea I. J Psychopharmacol. 2012;26(11):1408‑1416.
  15. Jacobsen PL, Mahableshwarkar AR, Chen Y, Chrones L, Clayton AH. J Sex Med. 2015;12(10):2036‑2048.
  16. Kambeitz JP, Howes OD. J Affect Disord. 2015;186:358-366.
  17. American Psychiatric Association. Depressive disorders. In: Diagnostic and Statistical Manual of Mental Disorders. 5th edition (DSM-5®). Arlington, VA: American Psychiatric Association; 2013:155‑188.
  18. Conradi HJ, Ormel J, de Jonge P. Psychol Med. 2011;41(6):1165-1174.